CAITONG SECURITIES·2025-11-12 13:50Investment Rating - The report assigns a "Buy" rating for JD Health (06618) for the first time [2]. Core Insights - JD Health aims to build a comprehensive health management platform centered on pharmaceutical and health product supply, leveraging its supply chain and logistics capabilities to become the largest pharmaceutical retail channel in China [8]. - The opening of online medical insurance purchasing rights is seen as a significant short-term catalyst for the industry, with expectations of increased online drug sales due to policy support [8]. - The company is expected to benefit from the increasing online penetration of pharmaceutical products and the opening of online medical insurance payment permissions, with projected revenues of 70.9 billion, 82.4 billion, and 94.2 billion RMB for 2025-2027 [8]. Summary by Sections Company Overview - JD Health, established in 2018, is a subsidiary of JD Group focused on healthcare, aiming to create a digital-driven health management platform covering the entire lifecycle of users [11]. - The company has a strong market position, with over 15,000 partnered pharmacies and a presence in more than 490 cities across China [11][29]. Pharmaceutical E-commerce Business - The report highlights the importance of the opening of online medical insurance purchasing rights and the increasing online penetration of pharmaceutical sales as key growth drivers [23]. - JD Health's strategy includes a combination of self-operated, platform-based, and instant retail channels to enhance service capabilities and meet urgent medication needs [26][29]. Financial Forecasts and Valuation - Revenue projections for JD Health are set at 70.9 billion, 82.4 billion, and 94.2 billion RMB for 2025, 2026, and 2027, respectively, with adjusted net profits expected to be 5.7 billion, 6.2 billion, and 7.2 billion RMB [34]. - The report anticipates a gradual improvement in gross margins and a decrease in marketing expenses over time, reflecting operational efficiencies [34]. Management and Shareholder Structure - The management team is experienced, with a stable ownership structure, where JD Jiankang Limited holds 67.16% of the shares, controlled by Liu Qiangdong [13][15].